Nebulized Liposomal Amphotericin B for Treatment of Pulmonary Infection Caused by Hormographiella aspergillata: Case Report and Literature Review - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Mycopathologia Année : 2017

Nebulized Liposomal Amphotericin B for Treatment of Pulmonary Infection Caused by Hormographiella aspergillata: Case Report and Literature Review

Jacques Cadranel
  • Fonction : Auteur
  • PersonId : 901162

Résumé

Invasive fungal infection is a serious complication following allogeneic hematopoietic stem cell transplantation. Pulmonary infection due to Hormographiella aspergillata is an uncommon condition associated with a high mortality rate. The susceptibility of H. aspergillata to available antifungal agents is not well established. We report for the first time a case of H. aspergillata lung infection that responded poorly to conventional treatment with liposomal amphotericin B (LAmB; 3 mg kg-1 of body weight per day) with renal damage at higher posology (5 mg kg-1 of body weight per day), but improved rapidly after addition of nebulized LAmB to intravenous LAmB (3 mg kg-1 of body weight per day). Successful treatment of our patient using nebulized LAmB would be worth evaluating in cases refractory to standard treatment or when the reference treatment may not be extended due to interaction or side effects.
Fichier non déposé

Dates et versions

hal-02534946 , version 1 (07-04-2020)

Identifiants

Citer

Cendrine Godet, Estelle Cateau, Blandine Rammaert, Marine Grosset, Gwenaël Le Moal, et al.. Nebulized Liposomal Amphotericin B for Treatment of Pulmonary Infection Caused by Hormographiella aspergillata: Case Report and Literature Review. Mycopathologia, 2017, 182 (7-8), pp.709-713. ⟨10.1007/s11046-017-0117-9⟩. ⟨hal-02534946⟩
146 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More